Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanguang Cao

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Cancers|August 26, 2023
Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer ImmunotherapyKaitlyn Maffuid, Yanguang Cao
Medicine|December 22, 2019
Plasma miR-200c-3p, miR-100-5p, and miR-1826 serve as potential diagnostic biomarkers for knee osteoarthritis: Randomized controlled trialsZhen Lai, Yanguang Cao
Journal of Pharmacokinetics and Pharmacodynamics|September 2, 2017
Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxelHua He, Yanguang Cao
International Journal of Molecular Sciences|April 3, 2021
In Translation: FcRn across the Therapeutic SpectrumTimothy Qi, Yanguang Cao
Antibodies (Basel, Switzerland)|April 25, 2022
A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph NodesEric Salgado, Yanguang Cao
The Journal of Pharmacology and Experimental Therapeutics|September 28, 2023
Utilizing a Proximity Dependent Labeling Strategy to Study Cancer-Immune Intercellular Interactions In Vitro and In VivoKaitlyn Maffuid, Yanguang Cao
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2023
Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case studyTimothy Qi, Yanguang Cao
CPT: Pharmacometrics & Systems Pharmacology|December 22, 2022
Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non-small cell lung cancerTimothy Qi, Yanguang Cao
Mathematical Biosciences and Engineering : MBE|February 2, 2021
Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodesEric Salgado, Yanguang Cao
Frontiers in Pharmacology|March 14, 2022
Physiological Considerations for Modeling <i>in vivo</i> Antibody-Target InteractionsTyler Dunlap, Yanguang Cao
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Cancers|August 26, 2023
Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer ImmunotherapyKaitlyn Maffuid, Yanguang Cao
Medicine|December 22, 2019
Plasma miR-200c-3p, miR-100-5p, and miR-1826 serve as potential diagnostic biomarkers for knee osteoarthritis: Randomized controlled trialsZhen Lai, Yanguang Cao
Journal of Pharmacokinetics and Pharmacodynamics|September 2, 2017
Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxelHua He, Yanguang Cao
International Journal of Molecular Sciences|April 3, 2021
In Translation: FcRn across the Therapeutic SpectrumTimothy Qi, Yanguang Cao
Antibodies (Basel, Switzerland)|April 25, 2022
A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph NodesEric Salgado, Yanguang Cao
The Journal of Pharmacology and Experimental Therapeutics|September 28, 2023
Utilizing a Proximity Dependent Labeling Strategy to Study Cancer-Immune Intercellular Interactions In Vitro and In VivoKaitlyn Maffuid, Yanguang Cao
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2023
Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case studyTimothy Qi, Yanguang Cao
CPT: Pharmacometrics & Systems Pharmacology|December 22, 2022
Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non-small cell lung cancerTimothy Qi, Yanguang Cao
Mathematical Biosciences and Engineering : MBE|February 2, 2021
Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodesEric Salgado, Yanguang Cao
Frontiers in Pharmacology|March 14, 2022
Physiological Considerations for Modeling <i>in vivo</i> Antibody-Target InteractionsTyler Dunlap, Yanguang Cao
Pageof 9